C07K 14/721
Steroid/thyroid hormone superfamily
Official title: {Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor}
C07K14/721 (Steroid/thyroid hormone superfamily) appears on 321 US grants and 377 published applications in this corpus.
Search patents in C07K- Granted patents
- 321
- Published applications
- 377
- Assignees
- 218
- Inventors
- 815
- Latest grant
- 14 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 5 | 0 |
| 1994 | 7 | 0 |
| 1995 | 6 | 0 |
| 1996 | 8 | 0 |
| 1997 | 15 | 0 |
| 1998 | 9 | 0 |
| 1999 | 12 | 0 |
| 2000 | 9 | 0 |
| 2001 | 9 | 3 |
| 2002 | 15 | 23 |
| 2003 | 9 | 39 |
| 2004 | 13 | 25 |
| 2005 | 5 | 12 |
| 2006 | 22 | 19 |
| 2007 | 18 | 12 |
| 2008 | 9 | 11 |
| 2009 | 11 | 12 |
| 2010 | 7 | 13 |
| 2011 | 5 | 6 |
| 2012 | 9 | 10 |
| 2013 | 5 | 13 |
| 2014 | 9 | 3 |
| 2015 | 5 | 9 |
| 2016 | 5 | 7 |
| 2017 | 5 | 23 |
| 2018 | 14 | 13 |
| 2019 | 17 | 20 |
| 2020 | 8 | 11 |
| 2021 | 10 | 18 |
| 2022 | 6 | 24 |
| 2023 | 11 | 10 |
| 2024 | 6 | 15 |
| 2025 | 14 | 19 |
| 2026 | 1 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Gene fusions for control of genetically modified cells14 Apr 2026US 12,599,665 B2A2 Biotherapeutics, Inc.
- CRISPR having or associated with destabilization domains7 Oct 2025US 12,435,320 B2Massachusetts Institute of Technology
- CAS9 proteins including ligand-dependent inteins26 Aug 2025US 12,398,406 B2President and Fellows of Harvard College
- Enzymatic nucleic acid molecules5 Aug 2025US 12,378,559 B2University of Essex Enterprises Limited
- Drug-resistant immune cells and methods of use thereof1 Jul 2025US 12,343,397 B2Regents of the University of Minnesota
- Gene therapy8 Oct 2026US 2026/0308598 A1
- Synthetic estrogen receptor (er)-derived peptide17 Sep 2026US 2026/0274922 A1The Texas A&M University System
- Method for predicting prognosis of metastatic hormone-sensitive prostate cancer30 Jul 2026US 2026/0218310 A1Jichi Medical University
- Crispr having or associated with destabilization domains4 Jun 2026US 2026/0152731 A1Massachusetts Institute of Technology
- Drug-Resistant Immune Cells and Methods of Use Thereof23 Apr 2026US 2026/0108610 A1Regents of the University of Minnesota
Most cited
By later US patents
- Hormone receptor-related bioassays234US 5,071,773 AThe Salk Institute for Biological Studies · 1991
- Biocompatible implant for the expression and in vivo secretion of a therapeutic substance151US 5,906,817 AInstitut Pasteur · 1999
- Polymeric carriers for non-covalent drug conjugation97US 5,252,713 ANeoRx Corporation · 1993
- Transgenic mouse for targeted recombination mediated by modified Cre-ER97US 7,112,715 B2Gie-Cerbm, Centre Europeen de Recherche en Biologie et en Medecine (GIE) · 2006
- Polynucleotides encoding insect steroid hormone receptor polypeptides and cells transformed with same93US 5,514,578 AThe Board of Trustees of the Leland Stanford University · 1996